Cargando…

A Comprehensive Overview of Targeted Therapy in Metastatic Renal Cell Carcinoma

Chemotherapy and immunotherapy failed to deliver decisive results in the systemic treatment of metastatic renal cell carcinoma. Agents representing the current standards operate on members of the RAS signal transduction pathway. Sunitinib (targeting vascular endothelial growth factor), temsirolimus...

Descripción completa

Detalles Bibliográficos
Autores principales: Mihály, Z, Sztupinszki, Z, Surowiak, P, Győrffy, B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bentham Science Publishers 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3434473/
https://www.ncbi.nlm.nih.gov/pubmed/22515521
http://dx.doi.org/10.2174/156800912802429265
_version_ 1782242450012635136
author Mihály, Z
Sztupinszki, Z
Surowiak, P
Győrffy, B
author_facet Mihály, Z
Sztupinszki, Z
Surowiak, P
Győrffy, B
author_sort Mihály, Z
collection PubMed
description Chemotherapy and immunotherapy failed to deliver decisive results in the systemic treatment of metastatic renal cell carcinoma. Agents representing the current standards operate on members of the RAS signal transduction pathway. Sunitinib (targeting vascular endothelial growth factor), temsirolimus (an inhibitor of the mammalian target of rapamycin - mTOR) and pazopanib (a multi-targeted receptor tyrosine kinase inhibitor) are used in the first line of recurrent disease. A combination of bevacizumab (inhibition of angiogenesis) plus interferon α is also first-line therapy. Second line options include everolimus (another mTOR inhibitor) as well as tyrosine kinase inhibitors for patients who previously received cytokine. We review the results of clinical investigations focusing on survival benefit for these agents. Additionally, trials focusing on new agents, including the kinase inhibitors axitinib, tivozanib, dovitinib and cediranib and monoclonal antibodies including velociximab are also discussed. In addition to published outcomes we also include follow-up and interim results of ongoing clinical trials. In summary, we give a comprehensive overview of current advances in the systemic treatment of metastatic renal cell carcinoma.
format Online
Article
Text
id pubmed-3434473
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Bentham Science Publishers
record_format MEDLINE/PubMed
spelling pubmed-34344732012-09-07 A Comprehensive Overview of Targeted Therapy in Metastatic Renal Cell Carcinoma Mihály, Z Sztupinszki, Z Surowiak, P Győrffy, B Curr Cancer Drug Targets Article Chemotherapy and immunotherapy failed to deliver decisive results in the systemic treatment of metastatic renal cell carcinoma. Agents representing the current standards operate on members of the RAS signal transduction pathway. Sunitinib (targeting vascular endothelial growth factor), temsirolimus (an inhibitor of the mammalian target of rapamycin - mTOR) and pazopanib (a multi-targeted receptor tyrosine kinase inhibitor) are used in the first line of recurrent disease. A combination of bevacizumab (inhibition of angiogenesis) plus interferon α is also first-line therapy. Second line options include everolimus (another mTOR inhibitor) as well as tyrosine kinase inhibitors for patients who previously received cytokine. We review the results of clinical investigations focusing on survival benefit for these agents. Additionally, trials focusing on new agents, including the kinase inhibitors axitinib, tivozanib, dovitinib and cediranib and monoclonal antibodies including velociximab are also discussed. In addition to published outcomes we also include follow-up and interim results of ongoing clinical trials. In summary, we give a comprehensive overview of current advances in the systemic treatment of metastatic renal cell carcinoma. Bentham Science Publishers 2012-09 2012-09 /pmc/articles/PMC3434473/ /pubmed/22515521 http://dx.doi.org/10.2174/156800912802429265 Text en © 2012 Bentham Science Publishers http://creativecommons.org/licenses/by/2.5/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.5/), which permits unrestrictive use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Article
Mihály, Z
Sztupinszki, Z
Surowiak, P
Győrffy, B
A Comprehensive Overview of Targeted Therapy in Metastatic Renal Cell Carcinoma
title A Comprehensive Overview of Targeted Therapy in Metastatic Renal Cell Carcinoma
title_full A Comprehensive Overview of Targeted Therapy in Metastatic Renal Cell Carcinoma
title_fullStr A Comprehensive Overview of Targeted Therapy in Metastatic Renal Cell Carcinoma
title_full_unstemmed A Comprehensive Overview of Targeted Therapy in Metastatic Renal Cell Carcinoma
title_short A Comprehensive Overview of Targeted Therapy in Metastatic Renal Cell Carcinoma
title_sort comprehensive overview of targeted therapy in metastatic renal cell carcinoma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3434473/
https://www.ncbi.nlm.nih.gov/pubmed/22515521
http://dx.doi.org/10.2174/156800912802429265
work_keys_str_mv AT mihalyz acomprehensiveoverviewoftargetedtherapyinmetastaticrenalcellcarcinoma
AT sztupinszkiz acomprehensiveoverviewoftargetedtherapyinmetastaticrenalcellcarcinoma
AT surowiakp acomprehensiveoverviewoftargetedtherapyinmetastaticrenalcellcarcinoma
AT gyorffyb acomprehensiveoverviewoftargetedtherapyinmetastaticrenalcellcarcinoma
AT mihalyz comprehensiveoverviewoftargetedtherapyinmetastaticrenalcellcarcinoma
AT sztupinszkiz comprehensiveoverviewoftargetedtherapyinmetastaticrenalcellcarcinoma
AT surowiakp comprehensiveoverviewoftargetedtherapyinmetastaticrenalcellcarcinoma
AT gyorffyb comprehensiveoverviewoftargetedtherapyinmetastaticrenalcellcarcinoma